A review of low-value regimens
Learn about the evidence surrounding several regimens that should often be avoided in favor of higher-quality options
A Review of Lurbinectedin and Topotecan
Subsequent therapy in recurrent, metastatic small cell lung cancer
A Review of Nab-Paclitaxel (Abraxane)
Treatment of non small cell lung cancer and breast cancer
A Review of Ramucirumab + Docetaxel
Subsequent therapy in metastatic non small cell lung cancer
A Review of Nivolumab + Ipilimumab
Initial treatment of metastatic non small cell lung cancer for PD-L1 ≥ 1%